| Metric | Value ($ M) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 129.86 | 23.2% | 59.3% |
| Total Income | 129.86 | 23.2% | 59.3% |
| Expenditure | 113.43 | 0.9% | 18.0% |
| PBT | — | ||
| Net Profit | 15.01 | 232.8% | 194.5% |
| OPM | 12.65% | 21.28pp | 30.58pp |
| NPM | 11.56% | 22.28pp | 31.05pp |
| EPS | 0.11 | 222.2% | 184.6% |
Arcutis Reports Q2 2026 Results: ZORYVE Revenue Up 59% YoY to $129.9M, Raises Full-Year Guidance
06 Aug 2026 · 6 Aug, 1:53 am
Summary
Arcutis Biotherapeutics reported strong second quarter 2026 financial results, driven by the continued growth of the ZORYVE franchise. Net product sales reached $129.9 million, a 59% increase year-over-year, and the company raised its full-year 2026 net product sales guidance to $525 million-$540 million. Significant progress was made in clinical and regulatory developments, including an expanded indication for ZORYVE cream and FDA acceptance of an sNDA for infants. Management highlighted the strength of the ZORYVE franchise and strategic initiatives to drive continued growth.
Key Highlights
- 1
ZORYVE net product revenue grew 59% year-over-year to $129.9 million in Q2 2026, with a 23% sequential increase from Q1 2026.
- 2
The company is raising its full-year 2026 net product sales guidance to a range of $525 million to $540 million.
- 3
Arcutis received FDA approval to expand the indication for ZORYVE cream 0.3% to children aged 2 and older, marking its seventh FDA approval since 2022.
- 4
The FDA accepted a supplemental New Drug Application (sNDA) for ZORYVE cream 0.05% for infants aged 3 to 24 months, with a target action date of February 23, 2027.
- 5
Enrollment was completed for the Phase 2 trial of ZORYVE foam 0.3% in vitiligo patients, with topline results anticipated in Q4 2026.
- 6
The company maintained positive operating cash flow for the quarter, generating $12.6 million.
- 7
Net income for the quarter was $15.0 million, or $0.11 per diluted share, a significant improvement from a net loss of $15.9 million in the prior year period.
Management Comments
Frank Watanabe
Our strong second quarter results reflect the continued strength of the ZORYVE franchise, the leading branded non-steroidal therapy across our three indications. With our investment in expanding our dermatology sales force and initiatives designed to simplify patient access, we are well positioned to drive continued growth and momentum through the second half of 2026. During the quarter, we also made significant progress in advancing our pipeline, highlighted by the FDA acceptance of our sNDA for ZORYVE cream 0.05% for infants with atopic dermatitis and completion of enrollment in our Phase 2 vitiligo study.
Informational and educational content only. Not investment advice.